Virosomes as Novel drug delivery System: An Overview

  • Narinder Singh CT Institute of Pharmaceutical Sciences
  • Surya Prakash Gautam CT Institute of Pharmaceutical Sciences,
  • Neelam Kumari CT Institute of Pharmaceutical Sciences
  • Rupinder Kaur CT Institute of Pharmaceutical Sciences
  • Manpreet Kaur CT Institute of Pharmaceutical Sciences
Keywords: Virosomes, Drug delivery, characterization, Application


Virosomes are reconstituted viral envelopes that can fill in as vaccines and as vehicles for cell conveyance of different macromolecules. The prospect of drug delivery and targeting systems utilizing virosomes is an intriguing innovative work field. Since virosomes are biocompatible, biodegradable, non-poisonous and non-autoimmunogenuic; endeavors have been made to use them as antibodies or adjuvants and also conveyance frameworks for drugs and organic for remedial purposes. The achievement of virosomal medicate conveyance relies on upon strategy used to set up the typified bioactive materials and fuse them into the virosomes. Virosome innovation could conceivably be utilized to convey peptides, nucleic acids or, then again qualities and medications like anti-toxins, anticancer agents, and steroids.

Author Biographies

Narinder Singh, CT Institute of Pharmaceutical Sciences

CT Institute of Pharmaceutical Sciences,
Shahpur, Jalandhar, Punjab, India

Surya Prakash Gautam, CT Institute of Pharmaceutical Sciences,

CT Institute of Pharmaceutical Sciences,
Shahpur, Jalandhar, Punjab, India

Neelam Kumari, CT Institute of Pharmaceutical Sciences

CT Institute of Pharmaceutical Sciences,
Shahpur, Jalandhar, Punjab, India

Rupinder Kaur, CT Institute of Pharmaceutical Sciences

CT Institute of Pharmaceutical Sciences,
Shahpur, Jalandhar, Punjab

Manpreet Kaur, CT Institute of Pharmaceutical Sciences

CT Institute of Pharmaceutical Sciences,
Shahpur, Jalandhar, Punjab, India


1. Targeting HER-2/neu with Antirat Neu Virosomes for Cancer Therapy, Cancer Res ;62;437-444
2. Stegmann T., Morselt HWM., Booy FP., Van Breemen JFL., Scherphof G., Wilschut J; Functional reconstitution of influenza virus envelopes; EMBO. J; 1987; 6;2651–9
3. Bron R., Ortiz A., Wilschut J; Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza-virus envelopes (virosomes); Biochem;1994; 33;9110–17
4. Schoen P., Bron R., Wilschut J Delivery of foreign substances to cells mediated by fusion-active reconstituted influenza virus envelopes (virosomes). J Liposome Res. 1993; 3:767–92.
5. ZinkernagelRM,HengartnerH;Regulationoftheimmuneresponsebyantigen.Science;2001;293;251-3
6. MetsikköK,vanMeerG,SimonsK.Reconstitutionofthefusogenicactivityofvesicularstomatitisvirus.EMBOJ;1986;5;3429–35
7. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache AM; The virosome concept for influenza vaccines;Vaccine; 2005; 23;26–38
8. Felnerova D., Viret JF., Glück R., Moser C; Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs; Curr Opin Biotechnol; 2004; 15;518–29
9. Bhamare G.,Karpe M., Kadam V; virosome drug and vaccine delivery system;wjpps;2014;3(10);437-447
10. Kaneda Y;Virosomes: evolution of the liposome as a targeted drug delivery system; Adv Drug Deliv Rev;2000; 43;197–205
11. Moser C., Amacker M; Influenza Virosomes as Antigen Delivery System. In: Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines; Springer US; 2013; 287-307.
12. Koppers-Lalic D., Hogenboom MM., Middeldorp JM., Pegtel DM; Virus modified exosomes for targeted RNA delivery; a new approach in nanomedicine ; Adv Drug Deliv Rev ;201365: 348-356.
13. Moser C., Amacker M., Zurbriggen R; Influenza virosomes as a vaccine adjuvant and carrier system; Expert Rev Vaccines;2011; 10; 437-446
14. Radha GV., Rani TS., Sarvani B; A review on proniosomal drug delivery system for targeted drug action. Journal of Basic and Clinical Pharmacy;2013;4;42-48
15. Soussan E., Cassel S., Blanzat M., Rico-Lattes I;Drug delivery by softmatter: matrix and vesicular carriers;Angew Chem Int Ed Engl;2011;48; 274-288
16. Bhattacharya S, Mazumder B; Virosomes: A Novel Strategy for Drug Delivery and Targeting; Bio Pharm International; 2011; 24: 9-14.
17. Huckriede A., Bungener L., ter Veer W., Holtrop M., Daemen T., et al;Influenza virosomes: combining optimal presentation of hemagglutinin with immune potentiating activity. Vaccine;2003;21;925-931
18. Goyal AK., Khatri K., Mishra N., Vyas SP ;New patents on mucosal delivery of vaccines. Expert Opinion on Therapeutic Patents;2008;8;1271-1288
19. Nordly P., Madsen HB., Nielsen HM., Foged C;Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immune stimulators. Expert Opin Drug Deliv ;2009;6; 657-672
20. Hatz C., van der Ploeg R., Beck BR., Frösner G., Hunt M, et al; Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years. Clin Vaccine Immunol; 2011;18; 885-887.
21. Miyanohara A; Preparation of vesicular stomatitis virus-G (VSV-G)conjugate and its use in gene transfer. Cold Spring Harb Protocol;2012;453-456
22. Torresi J., Johnson D., Wedemeyer H; Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol; 54: 1273-1285.
23. Krishnamachari Y., Geary SM., Lemke CD., Salem AK; Nanoparticle delivery systems in cancer vaccines. Pharm Res; 2011; 28;215-236.
24. Weeratna RD., McCluskie MJ; (2011) Recent Advances in Vaccine Adjuvants; Emerging Trends in Antibacterial Discovery: Answering the Call to Arms;2011;303-320.
25. Muhammad A., Champeimont J., Mayr UB., Lubitz W., Kudela P ; Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev Vaccines;2012;11; 97-116
26. Kudela P., Koller VJ., Lubitz W;Bacterial ghosts (BGs)--advanced antigen and drug delivery system;Vaccine ;2011;28; 5760-5767
27. Henriksen-Lacey M., Korsholm KS., Andersen P., Perrie Y., Christensen D; Liposomal vaccine delivery systems; Expert Opin Drug Deliv;2011;8: 505-519.
28. Wilschut J; Influenza vaccines: the virosome concept. Immunol Lett ;2009;122;118-121.
29. Joshi MD., Unger WJ., Storm G., van Kooyk Y., Mastrobattista E; targeting tumor antigens to dendritic cells using particulate carriers. J Control Release;2012;161; 25-37
30. Alving CR., Peachman KK., Rao M., Reed SG; Adjuvants for human vaccines. Curr Opin Immunol;2012; 24; 310-315
31. Reed SG., Bertholet S., Coler RN., Friede M ; New horizons in adjuvants for vaccine development. Trends Immunol;2009; 30; 23-32
32. O’Hagen DT., Wack A; Adjuvants: From Serendipity to Rational Discovery. Volcanology: Principles and Practice;2012; 348.
33. Zurbriggen R., Novak-Hofer I., Seelig A., Glück R;IRIV-adjuvant hepatitis A vaccine: in vivo absorption and biophysical characterization; Prog Lipid Res ;2000;39; 3-18
34. Wilschut J;Influenza vaccines: the virosome concept; Immunol Lett;2009; 122;118-121
35. Chen DL., Zheng D., Paller AS; Nano-Based Gene Therapy forDermatologic Diseases. In: Nanotechnology in Dermatology; Springer NewYork; 109-117.
36. Liu J., Wu J., Wang B., Zeng S., Qi F., et al; Oral vaccination with aliposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection. J Med Virol.Torchilin V Membrane Barriers for Bringing Drugs inside Cells and Inside Cell Organelles; J Membra Sci Technol; 2013;114.
37. Liu H., de Vries-Idema J., Ter Veer W., Wilschut J., Huckriede A; Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing; Med Microbiol Immunol;2013
38. Markovic I., Leikina E., Zhukovsky M., Zimmerberg J., Chernomordik LV;Synchronized activation and refolding of influenza hemagglutinin in multimericfusion machines; J Cell Biol;2001; 155; 833-844
39. Pastori C., Wahlestedt C; involvement of long noncoding RNAs in diseases affecting the central nervous system; RNA Biol;2012; 9; 860-870
40. Nardin E;The past decade in malaria synthetic peptide vaccine clinical trials; Hum Vaccin;2010; 6; 27-38
41. Rajat S., Mohd Yasir; Virosomes: A Novel Carrier for Drug Delivery; International Journal of Pharm Tech Research;2010;2(4); 2327-2339
42. 29. Huckriede A., Bungener L., ter Veer, W; Influenza virosomes: combining optimal presentation of hemagglutinin with immuno potentiating activity;Immuno potentiators in Modern Vaccines;2003;21(9-10); 925–931
43. Huckriede A., Bungene, L., Stegmann, T;The virosome concept for influenza vaccines;2005; 23(1);26–38
44. Kaneda Y; Virosomes: evolution of the liposome as a targeted drug delivery system;Adv Drug Deliv Rev;2000; 43(2-3); 197–205
45. Stegmann T., Morselt H.W., Booy, FP; Functional reconstitution of influenza virus envelopes; EMBO J;1987; 6(9): 2651-2659
46. Waelti E., Wegmann, N., Schwaninger, R; Targeting HER/neu with antirat Neu virosomes for cancer therapy; Cancer Res;2002;62(2); 437-444
47. jonge J., Holtrop M., Wilschut J;Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs;Gene Ther;2005;13(5); 400-411
48. Markus., SM., Annabelle, R., Francesca, B;. Induction of parasite growth inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen1;Infec Immun;2003; 71(8);4749-4758
49. Maria GC., Rinaldo Z., Marcello V;Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity; Virology ;2000;277(1); 111-118
50. Cusi MG., Del Vecchio., M.T, Terrosi C; Immune-Reconstituted Influenza Virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anti-cancer vaccine. J Immunol ;2005;174(11); 7210-16
51. Dijkstra J., Bron R., Wilschut J; Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes); J Immunol;1996; 157(3); 1028- 1036
52. Waelti ER., Glück R; Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes);Int J Cancer;1998; 77(5); 728-733
53. Pöltl-Frank F., Zurbriggen R., Helg A; Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine; Clin Exp Immunol ;1999;17(3): 496- 503
54. Scardino A., Correale P., Firat H; In vivo study of the GC/90IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse; Br J Cancer;2003;89(1); 199-205
55. Cusi MG., Zurbriggen R., Correale,P;. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.Vaccine;2002; 20(29-30); 3436-3442.
56. Enrico M., Pieter S., Jan W; targeting influenza virosomes to ovarian carcinoma cells; FEBS Letters; 2001; 509(1); 71-76.
57. Mischler R., Metcalfe IC;Inflexal V a trivalent virosome subunit influenza vaccine: production;2002; 20;17-23
58. Hatz C., Beck B., Steffen R., Genton B., d’Acremont V; Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travelers;2011;29; 5000-5006
59. Glück R;Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine;1999;17; 1782-1787
60. Hunziker IP., Grabscheid B., Zurbriggen R., Glück R., Pichler WJ; In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus.Int Immunol;2002;14; 615-626
61. Roy RM., Klein BS; Dendritic cells in antifungal immunity and vaccine design; Cell Host Microbe; 2012; 11: 436-446.
62. Waelti E, Wegmann N., Schwaninger R., Wetterwald A., Wingenfeld C; Targeting her-2/neu with antirat Neu virosomes for cancer therapy;Cancer Res;2002;62; 437-444
63. Genton B;Malaria vaccines: a toy for travelers or a tool for eradication?Expert Rev Vaccines;2008; 7; 597-611
How to Cite
Singh, N., Gautam, S.P., Kumari, N., Kaur, R. and Kaur, M. 2017. Virosomes as Novel drug delivery System: An Overview. PharmaTutor. 5, 9 (Sep. 2017), 47-55.

Most read articles by the same author(s)